COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

•Humoral immune response (measured by anti-S levels) increased in the cohort with subsequent doses of vaccine.•Sero-response from negative to positive anti-S above threshold occurred post-dose 4 and dose 5 in the whole cohort.•Patients who received anti-CD20 and anti-CD38 therapy had lower anti-S le...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2024-10, Vol.42 (24), p.126074, Article 126074
Hauptverfasser:	Bhella, Sita, Wilkin, Allison M., Hueniken, Katrina, Vijenthira, Abi, Sebag, Michael, Wang, Peng, Hicks, Lisa K., Hay, Annette E., Assouline, Sarit, Fraser, Graeme, Balitsky, Amaris, Mangel, Joy, Owen, Carolyn, Reiman, Anthony, Sehn, Laurie, Sutherland, Heather, Zhang, Tinghua, Arnold, Corey, Leite, Tamara, McCarthy, Erinn, Cooper, Curtis, Langlois, Marc-Andre, Arianne Buchan, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Antibodies Antigens Blood cancer Blood levels blood serum Canada Cancer therapies COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccines Drug dosages Enzyme-linked immunosorbent assay Fourth and subsequent COVID-19 vaccines Hematologic malignancies humoral immunity Immune response Immune response (humoral) Immune system Immunity (Disease) Immunogenicity Infections Leukemia Lymphoma Malignancy nucleocapsid Nucleocapsids Pandemics Patients prospective studies Proteins Questionnaires Severe acute respiratory syndrome coronavirus 2 Spike protein Stem cell transplantation vaccination Vaccines Viral diseases viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!